A Phase 1/2 interventional study of HP568 and HP568 in combination with palbociclib in Breast Cancer, sponsored by Hinova Pharmaceuticals Inc.. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-01-03.
Sponsored by Hinova Pharmaceuticals Inc. · Phase 1/2, Interventional, and Treatment
How we know · 6 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 111 studies testing palbociclib in Breast Neoplasms — 19 open to participants now, 43 under way, 9 of them phase 3. palbociclib · Breast Neoplasms.
Among the 111 studies testing palbociclib in Breast Neoplasms, this one is the 29th largest by planned enrollment, is one of 7 that started in 2025, is one of 5 in phase 1/2, reaches primary completion later than 18 of the 42 other live ones, and was the 102nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →19 of the 111 studies testing palbociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
Fudan University · Sites in China
Ages 18+
American Society of Clinical Oncology · Sites in United States
Ages 60+
Region Örebro County · Sites in Finland, Greece, Italy and 3 more countries
Ages 70+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+ · Women only
By country, each count listing its studies:
palbociclib: first FDA approval 2015 (IBRANCE), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, palbociclib is the treatment under test here. Read study by study →
111 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 68 · Phase 3 21 · Phase 4 5
First in 2008; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 204 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 100 across the 111 interventional studies. Of the 54 that completed or were terminated, 27 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 111 have an industry lead sponsor. The 10 most frequent:
Hinova Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Hinova Pharmaceuticals Inc. has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
13 of the studies testing palbociclib in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03820830Phase 3ETOP IBCSG Partners FoundationPalbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | 2026-12 |
| NCT02605486Memorial Sloan Kettering Cancer CenterPalbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC) | 2026-11 |
| NCT02738866Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPalbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | 2026-12 |
| NCT07130643Xinhong Wu, PhDEfficacy and Safety of CDK4/6 Inhibitors Combined With Endocrine Therapy in HR+/HER2- Neoadjuvant Therapy for Early Breast Cancer | 2026-12-20 |
| NCT03573648Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNeoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer | 2026-12-30 |
Add all 13 to your calendar (.ics) → With an account.
Among the 111 studies testing palbociclib in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 1/2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+/HER2- locally advanced or metastatic breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In the I/II stage: HP568 administered QD or BID for 28 day cycles.
Drug: HP568
In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
Drug: HP568 in combination with palbociclib
In the I/II stage: HP568 administered QD or BID for 28 day cycles.
Drug page: PalbociclibStudies of PalbociclibPalbociclib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.
Stage I: the incidence of TEAE of HP568
the percentage of patients with treatment-emergent Adverse events(TEAE), TEAE will be evaluated using CTCAE 5.0 standards.
Time frame: From the first administration dose to 30 calendar days after the last administration dose
Stage I: Incidence of dose limiting toxicity DLT, maximum tolerated dose MTD (if possible).
First cycle dose-limiting toxicities and determination of a maximum tolerated dose (MTD) if applicable among the doses evaluated
Time frame: 28 days
Stage III: Evaluate safety during the dose escalation phase of combination therapy
Adverse events will be evaluated using the CTCAE5.0 standard, and safety features will be based on the assessment of adverse events, including TEAE, laboratory indicators (blood routine, blood biochemistry, coagulation routine, blood lipids, urine routine), vital sign measurements (blood pressure, pulse, respiratory rate, and body temperature), physical examination, and 12 lead electrocardiogram.
Time frame: From the first administration dose to 30 calendar days after the last administration dose
Stage III: Evaluate tolerance during the dose escalation phase of combination therapy
First cycle dose-limiting toxicities and determination of a maximum tolerated dose (MTD) if applicable among the doses evaluated
Time frame: 28 days
Stage III: Evaluate the 24 week clinical benefit rate (CBR) during the dose escalation phase of combination therapy
According to RECIST 1.1 criteria, the proportion of subjects who achieve confirmed CR (complete response) and/or confirmed PR (partial response) within 24 weeks plus at least 24 weeks of SD (stable disease).
Time frame: Until all patients have completed 24 weeks administration
Stage II: 24 week clinical benefit rate (CBR)
According to RECIST 1.1 criteria, the proportion of subjects who achieve confirmed CR (complete response) and/or confirmed PR (partial response) within 24 weeks plus at least 24 weeks of SD (stable disease).
Time frame: Until all patients have completed 24 weeks administration
Stage I-III: Objective response rate (ORR)
According to RECIST 1.1 criteria, the proportion of subjects who achieve CR (complete response)+PR (partial response).
Time frame: Until all patients have completed study(approximately 2 years)
Stage I/III: 24 week clinical benefit rate (CBR)
According to RECIST 1.1 criteria, the proportion of subjects who achieve confirmed complete response (CR) and/or confirmed partial response (PR) within 24 weeks plus at least 24 weeks of stable disease (SD).
Time frame: Until all patients have completed 24 weeks administration
Stage I-III: Disease Control Rate (DCR)
The proportion of subjects who achieve response and disease stability (i.e. CR+PR+SD) after treatment.
Time frame: Until all patients have completed study(approximately 2 years)
Stage I-III: Progression free survival (PFS)
from the start of treatment until tumor progression or death from any cause, which comes first.
Time frame: Until all patients have completed study(approximately 2 years)
Stage I-III: Duration of response(DOR)
the time from the first onset of response (CR or PR) to disease progression
Time frame: Until all patients have completed study(approximately 2 years)
Stage I-III: Time to Response (TTR)
The time from the start of treatment to the first recorded achievement of response (CR or PR).
Time frame: Until all patients have completed study(approximately 2 years)
Stage I-II:Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)
Concentration-time curve (AUC) for single and multiple dose of HP568 will be assessed after a single dose and after multiple doses.
Time frame: on the first day of cycle 1 and cycle 2(each cycle is 28 days)
Stage I-II:Assessment of pharmacokinetic parameter maximum concentration (Cmax)
Maximum concentration (Cmax) for single and multiple dose of HP568 will be assessed after a single dose and after multiple doses.
Time frame: on the first day of cycle 1 and cycle 2(each cycle is 28 days)
Stage I-II: Assessment of pharmacokinetic parameter minimum concentration (Cmin).
minimum concentration (Cmin) for single and multiple dose of HP568 will be assessed after a single dose and after multiple doses.
Time frame: on the first day of cycle 1 and cycle 2 (each cycle is 28 days)
Stage I-II:Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)
Time to maximum concentration (Tmax) for HP568 will be assessed after a single dose and after multiple doses.
Time frame: on the first day of cycle 1 and cycle 2 (each cycle is 28 days)
Stage III:Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC)
Concentration-time curve (AUC) of HP568 and palbociclib will be assessed after single and multiple doses.
Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)
Stage III: Assessment of pharmacokinetic parameter maximum concentration (Cmax)
maximum concentration (Cmax) of HP568 and palbociclib will be assessed after a single dose and after multiple doses
Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)
Stage III: Assessment of pharmacokinetic parameter minimum concentration (Cmin)
Minimum concentration (Cmin) of HP568 and palbociclib will be assessed after a single dose and after multiple doses.
Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)
Stage III: Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)
Time to maximum concentration (Tmax) of HP568 and palbociclib will be assessed after a single dose and after multiple doses.
Time frame: on the Day 1 and Day 21 of cycle 1 (each cycle is 28 days)
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2025; primary completion for Jan 2026, 12 months later.
Of 164 industry-sponsored phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 75. This study's planned 12 months is below that.
Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palbociclib
Hinova Pharmaceuticals Inc.